AlphaStocks
4.6
Weak

RadNet, Inc. (RDNT)

As of Sep 20, 2026, RadNet, Inc. (RDNT) scores 4.6/10 on AlphaStocks' five-model composite, #124 of 168 Health Care stocks. At $76, RDNT trades 66% above its model fair value of $46.

Health Care / Health Care Services

S&P SmallCap 600

$75.97

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#124out of 168 in Health Care

Is RadNet, Inc. a Good Investment in 2026?

RadNet, Inc. (RDNT) scores 4.6 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating RadNet, Inc. as Neutral. However, the Lynch model rates it Caution. RadNet, Inc. currently trades 66% above its estimated fair value of $46. RadNet, Inc. ranks #124 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-1.7Market Cap6B

Estimated Fair Value

$45.8066% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Caution

Growth rate vs price (PEG)

Greenblatt

Neutral

Earnings yield 4.6% · ROC 19%

Frequently Asked Questions

Is RadNet, Inc. (RDNT) a good investment?
As of Sep 20, 2026, RadNet, Inc. (RDNT) scores 4.6/10 on AlphaStocks' five-model composite, #124 of 168 Health Care stocks. At $76, RDNT trades 66% above its model fair value of $46. That score is below average, suggesting caution.
What is RadNet, Inc.'s Piotroski F-Score?
RadNet, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RDNT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $46, RDNT appears overvalued. The stock currently trades 66% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does RDNT compare to other Health Care stocks?
RadNet, Inc. ranks #124 out of 168 stocks in the Health Care sector, placing it in the top 74% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about RDNT?
AlphaStocks evaluates RDNT using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Caution; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 4.6/10.

Similar Stocks

DVAMDDGX

Compare RDNT with

DVA vs RDNTMD vs RDNTDGX vs RDNT

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer